NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $317,255 | +14.6% | 551,556 | +40.1% | 0.04% | +8.6% |
| Q1 2023 | $276,766 | +16.1% | 393,749 | +273.2% | 0.04% | +12.9% |
| Q4 2022 | $238,427 | +15.2% | 105,499 | +62.9% | 0.03% | +6.9% |
| Q3 2022 | $207,000 | -2.4% | 64,771 | +15.9% | 0.03% | +3.6% |
| Q2 2022 | $212,000 | -10.5% | 55,891 | +27.2% | 0.03% | +3.7% |
| Q1 2022 | $237,000 | -2.5% | 43,932 | +144.5% | 0.03% | -3.6% |
| Q4 2021 | $243,000 | +6.6% | 17,965 | +41.7% | 0.03% | -3.4% |
| Q3 2021 | $228,000 | – | 12,675 | +66610.5% | 0.03% | – |
| Q1 2020 | $0 | -100.0% | 19 | -99.4% | 0.00% | -100.0% |
| Q4 2017 | $177,000 | – | 2,960 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |